INAB IN8BIO INC

IN8bio to Present at Biotech Showcase 2023 in San Francisco

IN8bio to Present at Biotech Showcase 2023 in San Francisco

  • Company to be in San Francisco January 9-11, 2023, during the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present at on Monday, January 9, 2023, and will also participate in a panel on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.

  • Biotech Showcase, January 9-10, 2023
    • Corporate presentation at 2:00pm PT on Monday, January 9, 2023
    • Gene & Cell Therapy: Innovative Approaches Making an Impact panel at 8:00am PT on Tuesday, January 10, 2023
    • Track: Yosemite A (Ballroom Level)

Interested parties can register to attend the event here:

The Biotech Showcase webcast will be available live and as a replay on .

Additionally, IN8bio management will be in San Francisco from January 9-11, 2023, during the 41st Annual J.P. Morgan Health Care Conference and will be available for meetings with investors.

Individuals interested in meeting with IN8bio management can contact .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio is also initiating INB-400, a corporate sponsored Phase 2 clinical trial in newly diagnosed glioblastoma following IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit

Company Contact:

IN8bio, Inc.

Patrick McCall

+ 1 646.600.6GDT (6438)

Investors & Media Contact:

Argot Partners



EN
03/01/2023

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Second Quarter 2025 Financial Results and Recent Busine...

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years.Received the Host Region USA East Abstract Award at ISCT 2025 for IN8bio’s DeltEx™ manufacturing platform.Presented preclinical data at ASGCT 2025 on INB-619, a novel gamma-delta T cell engager, and its ability to induce pan-gamma-delta T cell expansion and target CD19+ B c...

August 7, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Trea...

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recen...

June 9, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GB...

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving...

June 2, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T C...

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in pa...

May 14, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell ...

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- . (...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch